PRMT6 (D5A2N) Rabbit mAb 14641T from Cell Signaling Technology

Published Figures

Register or Sign In to View Figures.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
May 01 2023

Fig 1: PRMT6 acts as an oncogene to promote breast cancer progression. A) Analysis of PRMT6 mRNA expression in normal and breast cancer tissues within public datasets (TCGA BRAC, GSE72653, GSE27567, and GSE65194). Error bars represent the mean ± SD (*p <0.05, ** p < 0.01, *** p < 0.001). Two‐tailed unpaired t‐test. B) Kaplan–Meier survival analysis of PRMT6 expression in breast cancer or in TP53‐mutated breast cancer using the online tool Kaplan‐Meier plotter (http://kmplot.com/analysis/). “Number at risk” indicates the number of patients at risk at various times. C) Heat maps depicting the expression profile changes in control (shSCR) MDA‐MB‐231 cells and PRMT6‐knockdown (shPRMT6) MDA‐MB‐231 cells. D) GO enrichment analysis of differentially expressed genes in control cells and PRMT6‐ knockdown cells. Data analyzed using KOBAS (http://kobas.cbi.pku.edu.cn/). E) GSEA analysis of differentially expressed genes in control cells and PRMT6‐knockdown cells. GSEA analysis performed with Sangerbox tools. F,G) qRT‐PCR analysis of selected tumor suppressor genes and oncogenes in PRMT6‐knockdown (shPRMT6 #1, shPRMT 6 #2, and shPRMT6 #3) MDA‐MB‐231 cells. H,I) Tumor volumes in female NOD‐SCID mice (n = 5) following subcutaneous injection with MDA‐MB‐231 cells transfected with PRMT6 lentiviruses expression constructs or those carrying PRMT6‐specific shRNA. Western blot analysis of protein levels in separate tumors. J–M) qRT‐PCR analysis of selected tumor suppressor genes and oncogenes in PRMT6‐overexpressing and – knockdown tumors. F,G,J–M) Bars represent the mean ± SD of triplicate cell cultures (*p < 0.05, **p < 0.01, ***p < 0.001). Student's t‐test.
Register or Sign In to View Figures.

Heliyon
May 01 2020

Fig 2: PRMT6 expression is increased in the LV of DCM patients. (A Western blot analysis showing the increase in PRMT6 and H3R2Me2a expression in the heart of DCM patients (n = 5) compared to control hearts (n = 4). GATA-4 expression is shown in parallel. H3K4Me3 is decreased in DCM hearts. Total histone H3 and GAPDH were used as loading control. (B) shows the quantitative analysis of panel (A). (C) H3R2Me2a and H3K4Me3 levels were quantitated to show their reciprocal expression. Statistical significance was calculated by multiple unpaired t-tests assuming fewer assumptions without same scatter (SD) using GraphPad prism and data were graphically represented as mean ± SD. ∗p < 0.05. LV: left ventricle; DCM: dilated cardiomyopathy. The full blot images are available as supplementary material.
Register or Sign In to View Figures.

Molecular Medicine Reports
August 03 2020

Fig 3: Knockdown of PRMT6 suppresses lung adenocarcinoma development by activating p18 expression in vivo. (A) Images of tumors excised from BALB/c nude mice in the Scr, PRMT6 knockdown, and PRMT6 and p18 knockdown groups. (B) Tumor volume of xenograft tumors from mice in the Scr, PRMT6 knockdown, and PRMT6 and p18 knockdown groups were measured every 3 days. *P<0.05, **P<0.01. (C) Weight of xenograft tumors excised from mice in the Scr, PRMT6 knockdown, and PRMT6 and p18 knockdown groups were measured at the end of the experiment. *P<0.05, **P<0.01. (D) Body weight of A549 tumor-bearing mice were measured every 3 days. (E) Western blotting analysis of PRMT6 and p18 protein expression levels in xenograft tumors excised from mice in the Scr, PRMT6 knockdown and, PRMT6 and p18 knockdown groups. (F) Representative pathological images of PRMT6, p18 and Ki67 expression levels in xenograft tumors excised from mice in the Scr, PRMT6 knockdown and, PRMT6 and p18 knockdown groups. Scale bar, 50 µm. PRMT6, protein arginine methyltransferase 6; sh; short hairpin RNA; Scr, scramble; HE, hematoxylin and eosin; NS, non-significant.
Register or Sign In to View Figures.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
May 01 2023

Fig 4: PRMT6 modulates DNA repair to improve breast cancer cell proliferation and invasion. A) Establishment of the stably overexpressing PRMT6, knockdown (shPRMT6 #1, shPRMT6 #2, and shPRMT6 #3), and control, MDA‐MB‐231 and MCF‐7 cell lines. B) MNase digestion assay in PRMT6‐overexpressing MDA‐MB‐231 cells. MNase concentration: 1, 5, and 10 units. C) PRMT6 knockdown (shPRMT6 #1, shPRMT6 #2, and shPRMT6 #3) MDA‐MB‐231 cells treated with DOX or dimethyl sulfoxide (DMSO) for 2 h. DNA damage in these cells was measured using an alkaline comet assay (25 cells), and tail DNA is shown. D) Homologous repair (HR) efficiency determined via FACS, for PRMT6‐knockdown DR‐GFP U2OS cells (left panel). Nonhomologous end joining (NHEJ) efficiency, determined via FACS, for PRMT6‐knockdown EJ5‐U2OS cells (right panel). E) Cell proliferation curves, F) EdU assay, G) colony formation assay, H) transwell invasion assay, and I) western blot analysis of EMT markers expression, in stably overexpressing‐PRMT6 and PRMT6‐knockdown (shPRMT6 #1, shPRMT6 #2, and shPRMT6 #3) MDA‐MB‐231 and MCF‐7 cells. C–H) Bars represent the mean ± SD of three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001). Student's t‐test. shSCR, control scrambled shRNA.
Register or Sign In to View Figures.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
May 01 2023

Fig 5: The PRMT6/PARP1/CRL4B complex exerts transcriptional activity. A) ChIP‐seq analysis of PRMT6 and PARP1 chromosome features. B,C) Verification of ChIP‐seq results using qChIP analysis of genes identified in MDA‐MB‐231 cells. Results are represented as fold change over control; GAPDH served as the internal control. D) Binding profiles of PRMT6 and PARP1 on the representative target genes PER1, PER3, CSNK1A1, and BHLHE40. P1, PARP1; P6, PRMT6. E) Western blot analysis of indicated proteins in the stable PRMT6‐knockdown, PARP1‐knockdown, CUL4B‐knockdown, and DDB1‐knockdown MDA‐MB‐231 cells. F) mRNA levels of indicated genes in the PRMT6‐knockdown, PARP1‐knockdown, CUL4B‐knockdown, and DDB1‐knockdown MDA‐MB‐231 cells. G) ChIP and Re‐ChIP analysis in MDA‐MB‐231 cells with indicated antibodies. P1, PARP1; P6, PRMT6; 4B, CUL4B. H) Recruitment of indicated proteins to PER1, PER3, BHLHE40, and CSNK1A1 promoters in MDA‐MB‐231 cells after transfection with control shRNA (shSCR) or shRNAs targeting PRMT6, PARP1, CUL4B, or DDB1. Purified rabbit IgG was used as a negative control. I) Cell proliferation curves for control, PRMT6‐knockdown, PARP1‐knockdown, and PER3‐knockdown MDA‐MB‐231 cells. J) Colony formation assays for control, PRMT6‐knockdown, PARP1‐knockdown, and PER3‐knockdown MDA‐MB‐231 cells. K) Transwell invasion assays for control, PRMT6‐knockdown, PARP1‐knockdown, and PER3‐knockdown MDA‐MB‐231 cells. B,C,F,H,J,K) Bars represent the mean ± SD of three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001). Student's t‐test.

Be the first to write a review!

Citations:

(15)

Figures:

$153.00 Inquire

from
Cell Signaling Technology for
PRMT6 (D5A2N) Rabbit mAb

Cell Signaling Technology's PRMT6 (D5A2N) Rabbit mAb is a Rabbit monoclonal antibody. The PRMT6 (D5A2N) Rabbit mAb Antibody was generated using PRMT6 as the antigen. It reacts with Homo Sapiens, Human, Mouse, and Rat. This antibody has been shown to work in applications such as: Precipitation, Immunoprecipitation, and Western Blot.

Product Specs
ItemPRMT6 (D5A2N) Rabbit mAb
CompanyCell Signaling Technology
Price $153.00 Inquire
Catalog Number14641T
ClonalityMonoclonal
ReactivityH, M, R
ApplicationsW, IP
HostRabbit
Quantity20 µl
TargetPRMT6
NCBI Full Gene Nameprotein arginine methyltransferase 6
NCBI Gene AliasesHRMT1L6

Add to Compare List

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) PRMT6 inhibition or deficiency attenuates diabetic neuropathic pain in male mice and is associated with reduced spinal neuroinflammation, microgliosis, and altered p53-p21 signalingJournal of NeuroinflammationMay 29, 2026Yan Chu, Honghao Song, Mengqiu Deng, Yuanyuan Fang, Ruifeng Ding, Kesheng Huang, Xiaoyi Fan, Lei Peng, Yutong Yang, Huawei Wei, et al.quantitative data are presented in Supplementary Fig. 5. The following antibodies were used: PRMT6 (14641, CST, 1:1000), Iba1 (17198, CST, 1:1000), β-actin (AC026, ABclonal, 1:200000), NLRP3 (15101, CST, 1:1000),

(2) Hypoxia-induced PRMT6 expression promotes temozolomide chemoresistance in glioblastoma via G3BP1Journal of Translational MedicineJanuary 2, 2026Shuyang Chen, Peng Yu, Yongqing Sun, Yuting Yan, Boxiang Zhang, Guangyu Liacquired from OBiO Technology (Shanghai, China). Antibodies included: Anti-PRMT6 antibody (Cat No. 14641) and anti-ADMA antibody (Cat No. 13522) (CST; Boston, Massachusetts, USA), anti-HIF-1α (Cat No. 20960-1-AP),

(3) Nonchromatin regulatory functions of the histone variant H2A.B in SWI/SNF genomic depositionSci AdvJuly 25, 2025Xuanzhao Jiang, Jiayu Wen, Mary L. Nelson, Yasmin Dijkwel, Bradley Cairns, Uta-Maria Bauer, Gene Hart-Smith, Tatiana A. Soboleva, David J. Tremethick(Cell Signaling Technology, 13522S), PRMT1 (Merck Millipore, 07-404), PRMT6 (Cell Signaling Technology, 14641S), SMARCC1 (Cell Signaling Technology, 11956S; Proteintech, 17722-1-A), SMARCE1 (abcam, ab131328), TRA2B

(4) Protein arginine methyltransferase 4 modulates nitric oxide synthase uncoupling and cerebral blood flow in Alzheimer's diseaseJournal of cellular physiologyJune 1, 2024Clemons GA, Silva ACE, Acosta CH, Udo MSB, Tesic V, Rodgers KM, Wu CY, Citadin CT, Lee RH, Neumann JT, et al.dilutions as follows: PRMT4 (1:50, RRID: AB_2068436), PRMT6 (1:100, Cell Signaling Technology cat. 14641), AB (1:100, AB_2533902), pTau (1:1000, RRID: AB_2533749) eNOS (1:200, RRID: AB_10850618), nNOS (1:100,

(5) PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancerCell Death & DiseaseOctober 9, 2023Qianzhi Chen, Qingyi Hu, Yan Chen, Na Shen, Ning Zhang, Anshu Li, Lei Li, Junjun Liand rigorous testing confirmed the absence of any mycoplasma contamination. Antibodies for PRMT6 (#14641; Cell Signaling Technology), β-actin (#3700; Cell Signaling Technology), STAT3 (#8768; Cell Signaling Technology

(6) The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast TumorigenesisAdvanced science (Weinheim, Baden-Wurttemberg, Germany)May 1, 2023Yang T, Huang W, Ma T, Yin X, Zhang J, Huo M, Hu T, Gao T, Liu W, Zhang D, et al.anti‐γ‐catenin (610253), anti‐E‐cadherin (610181), and anti‐N‐cadherin (610920) from BD Bioscience; anti‐PRMT6 (14641S), anti‐PARP1 (9532T), and anti‐HER2 (4290) from Cell Signaling Technology; anti‐PER3 (12550‐1‐AP), anti‐LDHA

(7) A mycobacterial effector promotes ferroptosis-dependent pathogenicity and disseminationNature communicationsMarch 17, 2023Qiang L, Zhang Y, Lei Z, Lu Z, Tan S, Ge P, Chai Q, Zhao M, Zhang X, Li B, et al.immunofluorescence, ABclonal, A3155), Anti-PRMT6 antibody (1:1000 for immunoblotting, Cell Signaling Technologies, 14641S), Anti-H3 antibody (1:1000 for immunoblotting, Abcam, ab1791), Anti-α-Tubulin antibody (1:2000 for immunoblotting,

(8) The N⁶-methyladenosine demethylase ALKBH5 negatively regulates the osteogenic differentiation of mesenchymal stem cells through PRMT6Cell death & diseaseJune 4, 2021Li Z, Wang P, Li J, Xie Z, Cen S, Li M, Liu W, Ye G, Zheng G, Ma M, et al.ab38449, Abcam), SP7 (1 : 1000, ab209484, Abcam), RUNX2 (1 : 1000, ab23981, Abcam), PRMT6 (1 : 1000, 14641 S, Cell Signaling Technology), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1 : 3000, AF0006,

(9) PRMT6 serves an oncogenic role in lung adenocarcinoma via regulating p18Molecular Medicine ReportsAugust 3, 2020Jie Tang, Qinge Meng, Ruirui Shi, Youqi Xutemperature, Subsequently, the sections were incubated with an anti-PRMT6 primary antibody (1:250; cat. no. 14641; Cell Signaling Technology, Inc.), anti-p18 (1:250; cat. no. A8751; Abclonal Biotech Co., Ltd.) and

(10) Protein arginine methyltransferase 6 mediates cardiac hypertrophy by differential regulation of histone H3 arginine methylationHeliyonMay 1, 2020Raveendran VV, Al-Haffar K, Kunhi M, Belhaj K, Al-Habeeb W, Al-Buraiki J, Eyjolsson A, Poizat C.Antibodies and plasmid DNA Anti-PRMT6 antibody was purchased from Cell signaling technologies (cat# 14641S, Beverly, USA) and Abcam (Cat# ab104834, ab190902, Cambridge, USA). ANP (cat# SC-515701) and GAPDH antibodies

(11) PRMT6 Promotes Lung Tumor Progression via the Alternate Activation of Tumor-Associated MacrophagesMolecular cancer research : MCRJanuary 1, 2020Avasarala S, Wu PY, Khan SQ, Yanlin S, Van Scoyk M, Bao J, Di Lorenzo A, David O, Bedford MT, Gupta V, et al.peroxidase (HRP)-coupled secondary antibodies. The following antibodies were used for immunoblotting: PRMT6 (14641), and GAPDH (5174) antibodies were from Cell Signaling Technology, FLAG (F3165) and actin (A3853) were

(12) Inhibition of Protein arginine methyltransferase 6 reduces reactive oxygen species production and attenuates aminoglycoside- and cisplatin-induced hair cell deathTheranosticsJanuary 1, 2020He Y, Li W, Zheng Z, Zhao L, Li W, Wang Y, Li H.at room temperature and incubated with anti-PRMT6 (1:500 dilution; Cell Signaling Technology, Inc., 14641) and anti-GAPDH overnight at 4°C. The membranes were subsequently washed three times with TBST for 10

(13) PRMT6 mediates inflammation via activation of the NF-κB/p65 pathway on a cigarette smoke extract-induced murine emphysema modelTobacco induced diseasesJanuary 1, 2020He X, Li T, Luo L, Zeng H, Chen Y, Cai S.membranes were incubated overnight with rabbit polyclonal antibodies at 4°C. The antibodies were: PRMT6 #14641S and H3K4me3 #9727S, (Cell Signaling Technology, USA); H3R2me2a ab8046, (Abcam, USA); TNF-α Sc-8301 and

(14) The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPDNature communicationsJanuary 1, 0001"Günes Günsel G, Conlon TM, Jeridi A, Kim R, Ertüz Z, Lang NJ, Ansari M, Novikova M, Jiang D, Strunz M, et al."4 °C with antibodies against PRMT7 (Cat.No. NBP2-26135, 1:1000, Novus Biologicals), PRMT6 Cat. No. 14641, 1:1000, Cell Signaling Technology), mono-methylated arginine (Cat. No. 8015, 1:1000, Cell Signaling

(15) CARM1 drives triple-negative breast cancer progression by coordinating with HIF1AProtein & cellJanuary 1, 0001"Feng D, Gao J, Liu R, Liu W, Gao T, Yang Y, Zhang D, Yang T, Yin X, Yu H, et al."reagents The following antibodies were used: anti-PRMT1 (2449S), anti-CARM1 (12495S), anti-PRMT6 (14641S), anti-KLF4 (12173S), anti-CDK4 (12790S), anti-Rpb1 NTD (14958S) (Cell Signaling Technology, Danvers,

Be the First to Write a Review!

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Heliyon

Molecular Medicine Reports

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

PRMT6 (D5A2N) Rabbit mAb from Cell Signaling Technology

Cell Signaling Technology

Citations (15)

Reviews

PRMT6 (D5A2N) Rabbit mAb from Cell Signaling Technology

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map